re: (not) due for a bounce, one to watch! Everything is NOT on track alphamono. The ann. you refer to clearly states that there will be a 2-3 month delay in acheiving the CVT milestone. The previous May CVT deadline was carefully chosen by ABI management because they thought it was a very achievable deadline. They gave themselves plenty of time, and yet they are still forced to announce another delay. (You might recall that the previous ABI management was dismissed because of delays and setting unrealistic time frames etc). I suggest that you consider the possibility that there are still technical problems associated with stabilising membrane chemistry as well as sensitivity. Collectively, these delays are costly because 1), it pushes back the date that ABI will begin generating revenue (it could well be another 2-3 years before sensidx is released in North America), and 2), there are competing technologies being commercialised in North America.
ABI
ambri limited
